CAB-AXL-ADC + PD-1 inhibitor
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Cancer
Conditions
Non-Small-Cell Lung Cancer
Trial Timeline
Mar 17, 2021 → Jul 9, 2025
NCT ID
NCT04681131About CAB-AXL-ADC + PD-1 inhibitor
CAB-AXL-ADC + PD-1 inhibitor is a phase 2 stage product being developed by BioAtla for Non-Small-Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04681131. Target conditions include Non-Small-Cell Lung Cancer.
What happened to similar drugs?
7 of 20 similar drugs in Non-Small-Cell Lung Cancer were approved
Approved (7) Terminated (6) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04681131 | Phase 2 | Completed |
| NCT03425279 | Phase 1/2 | Completed |
Competing Products
20 competing products in Non-Small-Cell Lung Cancer